Effectiveness of the Novavax COVID-19 Vaccine in Reducing Clinically Defined Severe SARS-CoV-2 Infection in Individuals ≥ 12 Years of Age in the United States First published 03/07/2023 Last updated 02/07/2024 EU PAS number:EUPAS105521 Study Ongoing